EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches

Masatoshi Kanayama iD, Masaru Takenaka iD, Hidetaka Uramoto

Cancers · 02.11.2026 · 18 (21) · 3523

DOI: 10.3390/cancers18213523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 02.11.2026. Verfasst von Masatoshi Kanayama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC), but disease progression during or after immunotherapy remains a major therapeutic challenge. ICI failure is biologically and clinically heterogeneous and may manifest as primary resistance, acquired resistance, oligoprogressive disease, hyperprogressive disease, or disease recurrence following treatment discontinuation. These distinct patterns may require different therapeutic approaches. In this review, we summarize the current evidence for treatment strategies after immunotherapy failure in advanced NSCLC. Cytotoxic chemotherapy remains a key subsequent-line treatment, though evidence supporting enhanced chemotherapy sensitivity after prior ICI exposure is largely derived from retrospective or non-randomized studies. Docetaxel plus ramucirumab is an established treatment option, but its specific efficacy after ICI failure has not been confirmed in randomized trials. Local therapies, including stereotactic body radiotherapy and salvage surgery, may provide meaningful local control in carefully selected patients with oligoprogressive or otherwise localized disease, though prospective evidence remains limited. ICI rechallenge generally has limited activity after progression during active ICI treatment, whereas re-exposure may be considered in selected patients after planned treatment completion or discontinuation because of immune-related adverse events. Biomarker development, including tissue biomarkers, circulating tumor DNA, circulating tumor cells, and emerging tumor–immune profiling approaches, may facilitate more individualized treatment selection. Overall, management after immunotherapy failure should be guided by the pattern and tempo of disease progression, prior treatment history, and the feasibility of systemic and local treatment. Further prospective studies are needed to establish effective treatment strategies and validated biomarkers for patient selection.

Schlagwörter

Stichwörter der Autor:innen

biomarkerschemotherapyimmune checkpoint inhibitor rechallengeimmune checkpoint inhibitorsimmunotherapy failurelocal therapynon-small cell lung cancersalvage surgerytreatment resistance

Autor:innen und Institutionen

  • Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.

ORCID-Profile: Masatoshi Kanayama, Masaru Takenaka

Zitieren

APA

Kanayama, M., Takenaka, M., & Uramoto, H. (2026). Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches. Cancers, 18(21), 3523. https://doi.org/10.3390/cancers18213523

Vancouver

Kanayama M, Takenaka M, Uramoto H. Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches. Cancers. 2026;18(21):3523. doi:10.3390/cancers18213523

BibTeX
@article{Kanayama2026,
  author = {Kanayama, Masatoshi and Takenaka, Masaru and Uramoto, Hidetaka},
  title = {Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3523},
  doi = {10.3390/cancers18213523}
}
Kostenlos starten →